Company Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections.
Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.
The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19.
It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV.
Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2012 |
| IPO Date | Oct 30, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 75 |
| CEO | Jean-Pierre Sommadossi |
Contact Details
Address: 225 Franklin Street, Suite 2100 Boston, Massachusetts 02110 United States | |
| Phone | 857 284 8891 |
| Website | ateapharma.com |
Stock Details
| Ticker Symbol | AVIR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $24.00 |
| CIK Code | 0001593899 |
| CUSIP Number | 04683R106 |
| ISIN Number | US04683R1068 |
| Employer ID | 46-0574869 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jean-Pierre Sommadossi Ph.D. | Founder, Chairman, Chief Executive Officer and President |
| Andrea J. Corcoran J.D. | Chief Financial Officer, Executive Vice President of Legal and Secretary |
| Wayne Foster CPA | Executive Vice President of Finance and Chief Accounting Officer |
| Dr. Janet M. J. Hammond M.D., Ph.D. | Chief Development Officer |
| Dr. Maria Arantxa Horga M.D. | Chief Medical Officer |
| Jonae R. Barnes | Senior Vice President of Investor Relations and Corporate Communications |
| Ariyapadi N. Krishnaraj | Vice President of Marketing |
| Adel Moussa Ph.D. | Executive Vice President of Chemistry |
| Xiao-Jian Zhou Ph.D. | Executive Vice President of Early Stage Development |
| John F. Vavricka | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 16, 2024 | SCHEDULE 13D | Filing |
| Dec 10, 2024 | 144 | Filing |
| Nov 19, 2024 | EFFECT | Notice of Effectiveness |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | UPLOAD | Filing |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Sep 19, 2024 | 144 | Filing |